Evolving concepts of apoptosis in idiopathic pulmonary fibrosis

VJ Thannickal, JC Horowitz - Proceedings of the American Thoracic …, 2006 - atsjournals.org
Proceedings of the American Thoracic Society, 2006atsjournals.org
Idiopathic pulmonary fibrosis (IPF) is a chronic, relentlessly progressive fibrosing disease of
the lung of unknown etiology. Significant progress has been made in recent years in
elucidating key aspects of the pathobiology of IPF. Insights into disease pathogenesis have
come from studies of cell biology, growth factor/cytokine signaling, animal models of
pulmonary fibrosis, and human IPF cells and tissue. A consistent finding in the ultrastructural
pathology of IPF is alveolar epithelial cell injury and apoptosis. Another consistent finding in …
Idiopathic pulmonary fibrosis (IPF) is a chronic, relentlessly progressive fibrosing disease of the lung of unknown etiology. Significant progress has been made in recent years in elucidating key aspects of the pathobiology of IPF. Insights into disease pathogenesis have come from studies of cell biology, growth factor/cytokine signaling, animal models of pulmonary fibrosis, and human IPF cells and tissue. A consistent finding in the ultrastructural pathology of IPF is alveolar epithelial cell injury and apoptosis. Another consistent finding in the histopathology of human IPF, described as usual interstitial pneumonia, is the accumulation of aggregates of myofibroblasts in fibroblastic foci. The extent or profusion of fibroblastic foci in lung biopsies is strongly correlated with increased mortality in patients with IPF. There is emerging evidence that myofibroblasts in IPF/usual interstitial pneumonia, both in the in vivo microenvironment and during the process of differentiation in vitro, acquire resistance to apoptosis. Here, we review the current evidence and mechanisms for this apparent “apoptosis paradox” in the pathogenesis of IPF.
ATS Journals